카베딜롤 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "카베딜롤" in Korean language version.

refsWebsite

Global rank Korean rank

13doi.org

2^nd place

3^rd place

13nih.gov

4^th place

2drugs.com

399^th place

141^st place

2handle.net

102^nd place

307^th place

2clincalc.com

3,912^th place

2,490^th place

2semanticscholar.org

11^th place

310^th place

2fda.gov

447^th place

433^rd place

1books.google.com

3^rd place

9^th place

1ahajournals.org

3,608^th place

1,680^th place

1ed.ac.uk

1,871^st place

1,728^th place

ahajournals.org

circ.ahajournals.org

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, 외. (American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines) (2013년 10월 15일). “2013 AHA Guidelines for the Management of Heart Failure” (PDF). 《Circulation》 128 (16): e240–327. doi:10.1161/CIR.0b013e31829e8776. PMID 23741058.

books.google.com

Fischer J, Ganellin CR (2006). 《Analogue-based Drug Discovery》. John Wiley & Sons. 463쪽. ISBN 9783527607495.

clincalc.com

“The Top 300 of 2020”. 《ClinCalc》. 2022년 10월 7일에 확인함.
“Carvedilol - Drug Usage Statistics”. 《ClinCalc》. 2022년 10월 7일에 확인함.

doi.org

dx.doi.org

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, 외. (American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines) (2013년 10월 15일). “2013 AHA Guidelines for the Management of Heart Failure” (PDF). 《Circulation》 128 (16): e240–327. doi:10.1161/CIR.0b013e31829e8776. PMID 23741058.
Reis Filho JR, Cardoso JN, Cardoso CM, Pereira-Barretto AC (June 2015). “Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure”. 《Arquivos Brasileiros de Cardiologia》 104 (6): 502–6. doi:10.5935/abc.20150025. PMC 4484683. PMID 26131706.
Dargie HJ (May 2001). “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial”. 《Lancet》 357 (9266): 1385–1390. doi:10.1016/s0140-6736(00)04560-8. PMID 11356434. S2CID 1840228.
Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, 외. (June 2015). “Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention”. 《The American Journal of Cardiology》 115 (11): 1529–1538. doi:10.1016/j.amjcard.2015.02.057. PMID 25862157.
Cleland JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, 외. (January 2018). “Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials”. 《European Heart Journal》 39 (1): 26–35. doi:10.1093/eurheartj/ehx564. PMC 5837435. PMID 29040525.
Wong GW, Laugerotte A, Wright JM (August 2015). “Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension”. 《The Cochrane Database of Systematic Reviews》 2015 (8): CD007449. doi:10.1002/14651858.cd007449.pub2. PMC 6486308. PMID 26306578.
Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B (January 2017). “Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study”. 《BMC Medicine》 15 (1): 18. doi:10.1186/s12916-017-0781-0. PMC 5270217. PMID 28126029.
Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR (December 2002). “Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma”. 《The Journal of Heart and Lung Transplantation》 21 (12): 1290–5. doi:10.1016/s1053-2498(02)00459-x. PMID 12490274.
Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC (July 2017). “Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites” (PDF). 《Journal of Hepatology》 67 (1): 40–46. doi:10.1016/j.jhep.2017.02.005. hdl:20.500.11820/7afe3b88-1064-4da1-927e-4d4e867387eb. PMID 28213164.
Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY (October 2018). “Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices”. 《The Cochrane Database of Systematic Reviews》 2018 (10): CD011510. doi:10.1002/14651858.CD011510.pub2. PMC 6517039. PMID 30372514.
Lo GH, Chen WC, Wang HM, Yu HC (November 2012). “Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding”. 《Journal of Gastroenterology and Hepatology》 27 (11): 1681–7. doi:10.1111/j.1440-1746.2012.07244.x. PMID 22849337. S2CID 23494154.
Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian X, Lamparello A, Subnani R, Ferruzzi M, Pavlides C, Ho L, Hof PR, Teplow DB, Pasinetti GM (December 2011). “Carvedilol as a potential novel agent for the treatment of Alzheimer's disease”. 《Neurobiol Aging》 32 (12): 2321.e1–12. doi:10.1016/j.neurobiolaging.2010.05.004. PMC 2966505. PMID 20579773.
Bart J, Dijkers EC, Wegman TD, de Vries EG, van der Graaf WT, Groen HJ, Vaalburg W, Willemsen AT, Hendrikse NH (August 2005). “New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics”. 《Br J Pharmacol》 145 (8): 1045–51. doi:10.1038/sj.bjp.0706283. PMC 1576233. PMID 15951832.

drugs.com

“Carvedilol Monograph for Professionals”. 《Drugs.com》. AHFS. 2018년 12월 24일에 확인함.
“Carvedilol Use During Pregnancy”. 《Drugs.com》. 2018년 12월 24일에 확인함.

ed.ac.uk

pure.ed.ac.uk

Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC (July 2017). “Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites” (PDF). 《Journal of Hepatology》 67 (1): 40–46. doi:10.1016/j.jhep.2017.02.005. hdl:20.500.11820/7afe3b88-1064-4da1-927e-4d4e867387eb. PMID 28213164.

fda.gov

accessdata.fda.gov

“Coreg - Food and Drug Administration” (PDF).
“Drug Approval Package”. 《www.accessdata.fda.gov》. 2015년 11월 5일에 확인함.

handle.net

hdl.handle.net

World Health Organization (2021). 《World Health Organization model list of essential medicines: 22nd list (2021)》. Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC (July 2017). “Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites” (PDF). 《Journal of Hepatology》 67 (1): 40–46. doi:10.1016/j.jhep.2017.02.005. hdl:20.500.11820/7afe3b88-1064-4da1-927e-4d4e867387eb. PMID 28213164.

nih.gov

ncbi.nlm.nih.gov

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, 외. (American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines) (2013년 10월 15일). “2013 AHA Guidelines for the Management of Heart Failure” (PDF). 《Circulation》 128 (16): e240–327. doi:10.1161/CIR.0b013e31829e8776. PMID 23741058.
Reis Filho JR, Cardoso JN, Cardoso CM, Pereira-Barretto AC (June 2015). “Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure”. 《Arquivos Brasileiros de Cardiologia》 104 (6): 502–6. doi:10.5935/abc.20150025. PMC 4484683. PMID 26131706.
Dargie HJ (May 2001). “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial”. 《Lancet》 357 (9266): 1385–1390. doi:10.1016/s0140-6736(00)04560-8. PMID 11356434. S2CID 1840228.
Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, 외. (June 2015). “Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention”. 《The American Journal of Cardiology》 115 (11): 1529–1538. doi:10.1016/j.amjcard.2015.02.057. PMID 25862157.
Cleland JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, 외. (January 2018). “Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials”. 《European Heart Journal》 39 (1): 26–35. doi:10.1093/eurheartj/ehx564. PMC 5837435. PMID 29040525.
Wong GW, Laugerotte A, Wright JM (August 2015). “Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension”. 《The Cochrane Database of Systematic Reviews》 2015 (8): CD007449. doi:10.1002/14651858.cd007449.pub2. PMC 6486308. PMID 26306578.
Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B (January 2017). “Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study”. 《BMC Medicine》 15 (1): 18. doi:10.1186/s12916-017-0781-0. PMC 5270217. PMID 28126029.
Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR (December 2002). “Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma”. 《The Journal of Heart and Lung Transplantation》 21 (12): 1290–5. doi:10.1016/s1053-2498(02)00459-x. PMID 12490274.
Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC (July 2017). “Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites” (PDF). 《Journal of Hepatology》 67 (1): 40–46. doi:10.1016/j.jhep.2017.02.005. hdl:20.500.11820/7afe3b88-1064-4da1-927e-4d4e867387eb. PMID 28213164.
Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY (October 2018). “Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices”. 《The Cochrane Database of Systematic Reviews》 2018 (10): CD011510. doi:10.1002/14651858.CD011510.pub2. PMC 6517039. PMID 30372514.
Lo GH, Chen WC, Wang HM, Yu HC (November 2012). “Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding”. 《Journal of Gastroenterology and Hepatology》 27 (11): 1681–7. doi:10.1111/j.1440-1746.2012.07244.x. PMID 22849337. S2CID 23494154.
Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian X, Lamparello A, Subnani R, Ferruzzi M, Pavlides C, Ho L, Hof PR, Teplow DB, Pasinetti GM (December 2011). “Carvedilol as a potential novel agent for the treatment of Alzheimer's disease”. 《Neurobiol Aging》 32 (12): 2321.e1–12. doi:10.1016/j.neurobiolaging.2010.05.004. PMC 2966505. PMID 20579773.
Bart J, Dijkers EC, Wegman TD, de Vries EG, van der Graaf WT, Groen HJ, Vaalburg W, Willemsen AT, Hendrikse NH (August 2005). “New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics”. 《Br J Pharmacol》 145 (8): 1045–51. doi:10.1038/sj.bjp.0706283. PMC 1576233. PMID 15951832.

semanticscholar.org

api.semanticscholar.org

Dargie HJ (May 2001). “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial”. 《Lancet》 357 (9266): 1385–1390. doi:10.1016/s0140-6736(00)04560-8. PMID 11356434. S2CID 1840228.
Lo GH, Chen WC, Wang HM, Yu HC (November 2012). “Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding”. 《Journal of Gastroenterology and Hepatology》 27 (11): 1681–7. doi:10.1111/j.1440-1746.2012.07244.x. PMID 22849337. S2CID 23494154.